Marshall Wace North America’s Puma Biotechnology PBYI Stock Holding History

Marshall Wace North America’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,057	Closed	-$108K	–	1523
2019 Q3	$108K	Buy	+10,057	New	+$109K	﹤0.01%	1045
2019 Q1	–	Sell	-5,942	Closed	-$121K	–	1820
2018 Q4	$121K	Sell	5,942 -77,330	-93%	-$2.32M	﹤0.01%	1047
2018 Q3	$3.82M	Sell	83,272 -103,973	-56%	-$5.01M	0.03%	369
2018 Q2	$11.1M	Buy	187,245 +112,006	+149%	+$6.49M	0.06%	313
2018 Q1	$5.12M	Buy	75,239 +14,166	+23%	+$1.06M	0.03%	566
2017 Q4	$6.04M	Buy	61,073 +29,414	+93%	+$3.29M	0.03%	530
2017 Q3	$3.8M	Buy	+31,659	New	+$2.94M	0.02%	625
2017 Q2	–	Sell	-94,090	Closed	-$3.48M	–	1417
2017 Q1	$3.48M	Buy	+94,090	New	+$3.43M	0.03%	473

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace North America's PBYI Position: Q4 2019 in Review

Marshall Wace North America sold out of Puma Biotechnology (PBYI) in Q4 2019, closing a stake of 10,057 shares — an estimated $108K sold.

Marshall Wace North America first reported a position in PBYI in Q1 2017 and held it in 8 quarters. The position peaked at $11.1M in Q2 2018. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

Marshall Wace North America reported no remaining Puma Biotechnology position as of Q4 2019 after selling out during the quarter.
Marshall Wace North America sold 10,057 Puma Biotechnology shares in Q4 2019, an estimated $108K.
Marshall Wace North America first reported a position in Puma Biotechnology in Q1 2017 and held it in 8 quarters.
Marshall Wace North America's Puma Biotechnology position peaked at $11.1M in Q2 2018.
133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.